JP5732645B2 - Pgc−1の発現制御装置、並びに虚血性疾患の治療装置 - Google Patents
Pgc−1の発現制御装置、並びに虚血性疾患の治療装置 Download PDFInfo
- Publication number
- JP5732645B2 JP5732645B2 JP2011540332A JP2011540332A JP5732645B2 JP 5732645 B2 JP5732645 B2 JP 5732645B2 JP 2011540332 A JP2011540332 A JP 2011540332A JP 2011540332 A JP2011540332 A JP 2011540332A JP 5732645 B2 JP5732645 B2 JP 5732645B2
- Authority
- JP
- Japan
- Prior art keywords
- pgc
- ultrasonic
- expression
- irradiation
- expression control
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000017946 PGC-1 Human genes 0.000 title claims description 86
- 108700038399 PGC-1 Proteins 0.000 title claims description 86
- 208000023589 ischemic disease Diseases 0.000 title claims description 36
- 238000011282 treatment Methods 0.000 title description 58
- 230000001678 irradiating effect Effects 0.000 claims description 15
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 239000000523 sample Substances 0.000 description 80
- 230000005540 biological transmission Effects 0.000 description 39
- 230000033115 angiogenesis Effects 0.000 description 33
- 238000000034 method Methods 0.000 description 30
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 26
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 24
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 17
- 238000010186 staining Methods 0.000 description 15
- 206010003210 Arteriosclerosis Diseases 0.000 description 14
- 208000011775 arteriosclerosis disease Diseases 0.000 description 14
- 230000017531 blood circulation Effects 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 101001123331 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Proteins 0.000 description 12
- 102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 description 12
- 230000010355 oscillation Effects 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 10
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 10
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 10
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 10
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000004043 dyeing Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000013518 transcription Methods 0.000 description 9
- 230000035897 transcription Effects 0.000 description 9
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 8
- 230000001276 controlling effect Effects 0.000 description 8
- 238000011532 immunohistochemical staining Methods 0.000 description 8
- 230000000414 obstructive effect Effects 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 238000002604 ultrasonography Methods 0.000 description 8
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 6
- 101000742579 Homo sapiens Vascular endothelial growth factor B Proteins 0.000 description 6
- 101000742596 Homo sapiens Vascular endothelial growth factor C Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000006180 TBST buffer Substances 0.000 description 6
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 6
- 210000002414 leg Anatomy 0.000 description 6
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000002055 immunohistochemical effect Effects 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 4
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 4
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000010802 RNA extraction kit Methods 0.000 description 3
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000003081 coactivator Effects 0.000 description 3
- 239000007822 coupling agent Substances 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000013500 data storage Methods 0.000 description 2
- 230000008713 feedback mechanism Effects 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000004783 oxidative metabolism Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012276 Endovascular treatment Methods 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
- 101000945735 Homo sapiens Parafibromin Proteins 0.000 description 1
- 101150003028 Hprt1 gene Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102100034743 Parafibromin Human genes 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 101000688200 Prevotella intermedia Alkaline phosphatase Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 238000005206 flow analysis Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 230000008437 mitochondrial biogenesis Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000002210 silicon-based material Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0078—Ultrasound therapy with multiple treatment transducers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Sustainable Development (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Percussion Or Vibration Massage (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
(第1の実施形態)
本発明に係るPGC−1の発現制御装置の一実施形態について、図1を参照して以下に説明する。図1は、本発明に係るPGC−1の発現制御装置1の一実施形態を示すブロック図である。図1に示すように、本発明に係るPGC−1の発現制御装置1は、本体部10及びプローブ20により構成されている。本体部10には、ユーザインターフェース(UI)11、コントローラ(制御手段)12、電源部13及び1つ以上の超音波送信部14(超音波照射手段)が備えられている。プローブ20には、1つ以上の探触子(超音波放出端子)21が備えられている。プローブ20は、本体部10とは独立したハウジング内に設けられていてもよく、本体部10と同一ハウジング内に、本体部10とは独立して設けられていてもよい。また、プローブ20を本体部10にケーブル等により接続し、プローブ20が本体部20から離れた位置で動作し得るように構成していてもよい。
本発明に係るPGC−1の発現制御装置の他の実施形態について、図2を参照して以下に説明する。図2は、本発明に係るPGC−1の発現制御装置1aの他の実施形態を示すブロック図である。図2に示すように、本実施形態に係るPGC−1の発現制御装置1aは、超音波送信部14が1つである点と、切り替えスイッチ15を備えている点とにおいて第1の実施形態のPGC−1の発現制御装置1と異なっている。本実施形態においては、第1の実施形態と異なる点についてのみ詳細に説明し、他の説明は省略する。
次に、PGC−1の発現制御装置1及び1aのプローブ20又は20aに備えられた探触子21の構成について、図3(a)及び(b)を参照して説明する。図3(a)及び(b)は、本発明に係るPGC−1の発現制御装置の1及び1aの探触子21の構成例を示す模式図である。図3中(a)は、探触子21の上面図を示しており、図3中(b)は探触子21の断面図を示している。
本発明に係る虚血性疾患の治療装置は、上述した本発明に係るPGC−1の発現制御装置1を備えている。本発明に係る虚血性疾患の治療方法は、生体に超音波を照射してPGC−1の発現を促進する発現促進工程を包含している。また、本発明に係る虚血性疾患の治療方法は、生体に超音波を照射する超音波照射工程をさらに包含していてもよい。本発明に係る虚血性疾患の治療方法において、発現制御工程及び超音波照射工程は本発明に係るPGC−1の発現制御装置1によって行うことができる。
(実施例1)
ヒト間葉系幹細胞(MSC)を用いて、超音波照射によるPGC−1及びVEGFの発現量の変化について調査した。
実施例1と同様に調製したヒト間葉系幹細胞において、超音波照射によるHIF−1αの発現量の変化を実施例1と同様に調査した。結果を図8に示す。図8に示すように、HIF−1αのRNA発現量は、超音波照射によって変化しなかった。
血管新生モデルマウスを用いて、超音波照射によるPGC−1及びVEGFの発現量の変化について調査した。
−80℃で保存していた凍結組織を、クリオスタット(LEICA CM1950)内で−25℃に戻し、5μmの厚みになるように薄切した。薄切組織切片をAPSコートスライドガラス(S8441;松浪硝子工業株式会社製)に接着させた。室温で30分間風乾させ、10%中性緩衝ホルマリン液中(062−01661;和光純薬工業株式会社製)で10分間固定した。固定した組織切片をマイヤーヘマトキシリン(サクラファインテックジャパン株式会社製)で12分間染色後、温水発色し、さらにエオジン(サクラファインテックジャパン株式会社製)で10分間染色後、流水水洗した。染色後の組織切片の脱水及び透徹処理を行い、封入した。封入した組織切片について、倒立式光学顕微鏡(OLYMPUS IX81)により顕微鏡写真を撮影した。結果を図15〜17に示す。
−80℃で保存していた凍結組織を、クリオスタット(LEICA CM1950)内で−25℃に戻し、5μmの厚みになるように薄切した。薄切組織切片をAPSコートスライドガラス(S8441;松浪硝子工業株式会社製)に接着させた。室温で30分間風乾させ、アルカリ性ホスファターゼ染色キットを用い、定法に従ってアルカリ性ホスファターゼ染色を行った。染色した組織切片を、倒立式光学顕微鏡(OLYMPUS IX81)により顕微鏡写真を撮影した(図18〜20)。
−80℃で保存していた凍結組織(虚血側下肢)を、クリオスタット(LEICA CM1950)内で−25℃に戻し、5μmの厚みになるように薄切した。薄切組織切片をAPSコートスライドガラス(S8441;松浪硝子工業株式会社製)に接着させた。室温で30分間風乾させ、10%中性緩衝ホルマリン液中で10分間固定した。TBSTで十分に洗浄し、1.5%過酸化水素水加メタノール処理により内在性ペルオキシダーゼを失活させた。TBSTで十分に洗浄した後、TBST中に溶解させた0.5%blocking reagent(1096176;ロシュダイアグノスティックス株式会社)を用いて、ブロッキング処理を室温で1時間行った。
10、10a 本体部
11 ユーザインターフェース
12 コントローラ(制御手段)
13 電源部
14 超音波送信部(超音波照射手段)
15 切り替えスイッチ
20、20a プローブ
21 探触子(超音波放出端子)
Claims (5)
- 対象に超音波を照射する超音波照射手段を備え、
周波数が0.5〜3MHz±10%の範囲内の超音波を上記対象に照射するように上記超音波照射手段を制御する制御手段をさらに備えており、
上記超音波の出力を制御するために、上記対象における超音波照射部位のPGC−1の発現量を上記制御手段にフィードバックすることを特徴とする、PGC−1の発現制御装置。 - 上記制御手段は、上記対象に超音波を1日あたり20〜40分間±10%の範囲内で照射するように上記超音波照射手段を制御することを特徴とする請求項1に記載のPGC−1の発現制御装置。
- 上記超音波照射手段は、上記対象に対して媒体を介して非侵襲的に接触し、上記対象に照射する超音波を放出する少なくとも1つの超音波放出端子をさらに備えていることを特徴とする請求項1又は2に記載のPGC−1の発現制御装置。
- 複数の上記超音波放出端子のそれぞれを時分割で順次駆動して超音波を放出させるように上記超音波照射手段を制御する制御手段を備えていることを特徴とする請求項3に記載のPGC−1の発現制御装置。
- 請求項1又は2に記載のPGC−1の発現制御装置を備えたことを特徴とする虚血性疾患の治療装置。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2009/006025 WO2011058600A1 (ja) | 2009-11-11 | 2009-11-11 | Pgc-1の発現制御装置、並びに虚血性疾患の治療装置及び治療方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2011058600A1 JPWO2011058600A1 (ja) | 2013-03-28 |
JP5732645B2 true JP5732645B2 (ja) | 2015-06-10 |
Family
ID=43991282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011540332A Active JP5732645B2 (ja) | 2009-11-11 | 2009-11-11 | Pgc−1の発現制御装置、並びに虚血性疾患の治療装置 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20120232437A1 (ja) |
EP (1) | EP2500409B1 (ja) |
JP (1) | JP5732645B2 (ja) |
KR (1) | KR101908736B1 (ja) |
CN (1) | CN102666832B (ja) |
AU (1) | AU2009355181A1 (ja) |
WO (1) | WO2011058600A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016195618A (ja) * | 2013-09-18 | 2016-11-24 | 日本シグマックス株式会社 | 血管内皮機能障害を処置する装置、ならびにPLCγ1、ERK5またはERK1/2の活性化制御方法 |
CN105726190B (zh) * | 2014-12-12 | 2019-10-29 | 北京东方百奥医药开发有限公司 | 一种用于男性勃起功能障碍的脉冲超声治疗设备 |
CN108136204B (zh) * | 2015-10-15 | 2020-10-30 | 法玛科技顾问股份有限公司 | 超音波刺激头盔 |
CN105944243A (zh) * | 2016-05-12 | 2016-09-21 | 段俊丽 | 一种eNOS表达与活化的调控装置及周围动脉疾病的治疗装置 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003061756A2 (en) * | 2002-01-23 | 2003-07-31 | The Regents Of The University Of California | Implantable thermal treatment method and apparatus |
JP2003526403A (ja) * | 1999-06-14 | 2003-09-09 | エクソジェン インコーポレイテッド | 低強度超音波によるキャビテーション誘発組織治療の方法およびキット |
WO2004112889A2 (en) * | 2003-06-18 | 2004-12-29 | The Regents Of The University Of California | Ultrasound devices and methods for treating ischemia and other cardiovascular disorders |
JP2005523132A (ja) * | 2002-04-24 | 2005-08-04 | エクソジェン インコーポレイテッド | 結合組織の超音波治療のための方法及び器具 |
JP2005304918A (ja) * | 2004-04-23 | 2005-11-04 | Teijin Pharma Ltd | 創傷治療装置 |
WO2008124843A2 (en) * | 2007-04-10 | 2008-10-16 | Rush University Medical Center | Combined use of ultrasound and growth factors to stimulate bone formation |
JP2011527931A (ja) * | 2008-07-14 | 2011-11-10 | アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ | 超音波を使用して細胞活動を調節するための方法およびデバイス |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR8107560A (pt) | 1981-11-19 | 1983-07-05 | Luiz Romariz Duarte | Estimulacao ultra-sonica da consolidacao de fraturas osseas |
US5413550A (en) * | 1993-07-21 | 1995-05-09 | Pti, Inc. | Ultrasound therapy system with automatic dose control |
US20080015569A1 (en) * | 2005-02-02 | 2008-01-17 | Voyage Medical, Inc. | Methods and apparatus for treatment of atrial fibrillation |
-
2009
- 2009-11-11 WO PCT/JP2009/006025 patent/WO2011058600A1/ja active Application Filing
- 2009-11-11 KR KR1020127012409A patent/KR101908736B1/ko active IP Right Grant
- 2009-11-11 AU AU2009355181A patent/AU2009355181A1/en not_active Withdrawn
- 2009-11-11 US US13/508,814 patent/US20120232437A1/en not_active Abandoned
- 2009-11-11 JP JP2011540332A patent/JP5732645B2/ja active Active
- 2009-11-11 CN CN200980162355.8A patent/CN102666832B/zh not_active Expired - Fee Related
- 2009-11-11 EP EP09851235.3A patent/EP2500409B1/en not_active Not-in-force
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003526403A (ja) * | 1999-06-14 | 2003-09-09 | エクソジェン インコーポレイテッド | 低強度超音波によるキャビテーション誘発組織治療の方法およびキット |
WO2003061756A2 (en) * | 2002-01-23 | 2003-07-31 | The Regents Of The University Of California | Implantable thermal treatment method and apparatus |
JP2005523132A (ja) * | 2002-04-24 | 2005-08-04 | エクソジェン インコーポレイテッド | 結合組織の超音波治療のための方法及び器具 |
WO2004112889A2 (en) * | 2003-06-18 | 2004-12-29 | The Regents Of The University Of California | Ultrasound devices and methods for treating ischemia and other cardiovascular disorders |
JP2005304918A (ja) * | 2004-04-23 | 2005-11-04 | Teijin Pharma Ltd | 創傷治療装置 |
WO2008124843A2 (en) * | 2007-04-10 | 2008-10-16 | Rush University Medical Center | Combined use of ultrasound and growth factors to stimulate bone formation |
JP2011527931A (ja) * | 2008-07-14 | 2011-11-10 | アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ | 超音波を使用して細胞活動を調節するための方法およびデバイス |
Also Published As
Publication number | Publication date |
---|---|
KR20120115228A (ko) | 2012-10-17 |
CN102666832A (zh) | 2012-09-12 |
JPWO2011058600A1 (ja) | 2013-03-28 |
US20120232437A1 (en) | 2012-09-13 |
KR101908736B1 (ko) | 2018-10-16 |
CN102666832B (zh) | 2014-07-02 |
EP2500409A4 (en) | 2013-04-24 |
EP2500409B1 (en) | 2015-01-07 |
EP2500409A1 (en) | 2012-09-19 |
WO2011058600A1 (ja) | 2011-05-19 |
AU2009355181A1 (en) | 2012-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Du et al. | Targeted myocardial delivery of GDF11 gene rejuvenates the aged mouse heart and enhances myocardial regeneration after ischemia–reperfusion injury | |
Nishida et al. | Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo | |
Hanawa et al. | Low-intensity pulsed ultrasound induces angiogenesis and ameliorates left ventricular dysfunction in a porcine model of chronic myocardial ischemia | |
Rivard et al. | Age-dependent impairment of angiogenesis | |
Fujii et al. | Ultrasound-targeted gene delivery induces angiogenesis after a myocardial infarction in mice | |
Liu et al. | Angiogenesis assays for the evaluation of angiogenic properties of orthopaedic biomaterials–A general review | |
Zhang et al. | Enhancing efficacy of stem cell transplantation to the heart with a PEGylated fibrin biomatrix | |
EP1671627B1 (en) | Improvement of cell therapy and tissue regeneration in patients with cardiovascular and neurological diseases by means of shockwaves | |
Azizi et al. | Post-infarct treatment with [Pyr1] apelin-13 improves myocardial function by increasing neovascularization and overexpression of angiogenic growth factors in rats | |
Madeddu et al. | Murine models of myocardial and limb ischemia: diagnostic end-points and relevance to clinical problems | |
Conze et al. | Effect of autologous adipose tissue-derived mesenchymal stem cells on neovascularization of artificial equine tendon lesions | |
JP5732645B2 (ja) | Pgc−1の発現制御装置、並びに虚血性疾患の治療装置 | |
US20200297775A1 (en) | Enhanced direct cardiac reprogramming | |
JP2019521976A (ja) | Vegf−aポリペプチドをコードする改変rna、製剤、およびそれに関連する使用 | |
CN108778311A (zh) | 用于治疗心脏纤维化的药物组合物 | |
CN102421894A (zh) | 用于促进局部缺血性和糖尿病性创面愈合的组合物、试剂盒和方法 | |
RU2449799C2 (ru) | Средство для осуществления терапевтического ангиогенеза и способ его осуществления | |
An et al. | The therapeutic role of VEGF-expressing muscle-derived stem cells in acute penile cavernosal injury | |
Shiba et al. | Models for the study of angiogenesis | |
WO2015041254A1 (ja) | 血管内皮機能障害を処置する装置、血管内皮機能障害を処置する方法ならびにPLCγ1、ERK5またはERK1/2の活性化制御方法 | |
KR20140054622A (ko) | 충격파를 이용한 시험관 내에서 체내 혈류를 모방하는 환경을 제공하는 방법 | |
Chen et al. | Ex Vivo Imaging of Ultrasound-Stimulated Metabolic Activity in Rat Pancreatic Slices | |
Comeau | Ultrasound standing wave field technology for cell patterning and microvessel network formation in vitro and in situ | |
WO2024028653A1 (en) | A human tissue model for heart failure with preserved ejection fraction (hfpef) for the discovery of therapeutics and therapeutic targets | |
GUTZMANN | FIBRONECTIN, COLLAGEN α1, TYPE III, TGFβ DESMIN, AND α-SMA, IN LAMINITIS USING IN VITRO AND EX VIVO TECHNIQUES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140114 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140819 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141119 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20141121 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20141217 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150217 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150316 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5732645 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |